docetaxel anhydrous has been researched along with Esophageal Neoplasms in 426 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (0.94) | 18.2507 |
| 2000's | 81 (19.01) | 29.6817 |
| 2010's | 267 (62.68) | 24.3611 |
| 2020's | 74 (17.37) | 2.80 |
| Authors | Studies |
|---|---|
| Bhagia, P; Doi, T; Han, S; Ishihara, R; Iwakami, K; Kato, K; Kawakami, H; Kojima, T; Moriwaki, T; Muro, K; Nagashima, F; Ogata, T; Satoh, T; Takami, T; Yatsuzuka, N | 1 |
| Bo, C; Dong, L; Guo, L; Guo, Y; He, L; Zhang, S; Zhang, Y; Zheng, Z | 1 |
| Baba, H; Emi, Y; Hamai, Y; Hihara, J; Kitagawa, Y; Kunisaki, C; Maehara, Y; Matsubara, H; Morita, S; Nagano, H; Nakashima, Y; Oki, E; Otsuji, E; Saeki, H; Takeuchi, H; Tanaka, Y; Tomizuka, K; Ueno, T; Yoshida, K | 1 |
| Hazarika, M; Kumar, G; Mallik, S; Roy, PS; Saikia, BJ; Sarangi, SS; Talukdar, A | 1 |
| Chang, DD; Feng, ST; Guo, QK; Lei, YY; Li, HJ; Liu, LZ; Xu, BC; Xu, M; Yan, J; Yao, W; Zhu, Y; Zhu, ZH | 1 |
| Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM | 1 |
| Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Nomura, H; Tsuji, D; Ueno, S; Yano, T | 1 |
| Bao, Y; Cai, J; Chen, J; Chen, M; Dong, B; Du, X; Guan, N; He, H; Hu, J; Hu, W; Huang, J; Huang, R; Jiang, H; Kong, Y; Li, J; Liang, X; Liao, Z; Liu, L; Liu, Y; Liu, Z; Ma, J; Pu, J; Qiu, G; Sun, Z; Tao, G; Tao, H; Wang, W; Xu, Y; Yang, X; Zeng, M; Zheng, X; Zhou, J; Zhu, W; Zhuang, T | 1 |
| Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D | 1 |
| Akaishi, R; Ando, R; Fukutomi, T; Horie, Y; Kamei, T; Okamoto, H; Ozawa, Y; Sato, C; Shinozaki, Y; Takahashi, K; Taniyama, Y; Unno, M | 1 |
| Ajani, JA; Arkenau, HT; Bi, Q; Borg, C; Chen, J; Chen, Z; Ding, N; Hara, H; He, Z; Kato, K; Kim, SB; Li, L; Lin, CY; Lordick, F; Luo, Q; Niu, Z; Pazo-Cid, R; Satoh, T; Shen, L; Shi, J; Shu, Y; Sun, JM; Tao, A; Van Cutsem, E; Wang, J; Yi, T; Yu, G; Yu, X; Zhang, L; Zhao, K | 1 |
| Inaki, N; Kinoshita, J; Moriyama, H; Nakamura, K; Ninomiya, I; Okamoto, K; Saito, H; Shimada, M; Terai, S; Yamaguchi, T | 1 |
| Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB | 1 |
| Asadi, J; Jafari, SM; Mohammadi, Z | 1 |
| Bartels, A; Brossart, P; Feldmann, G; Giordano, FA; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, M; Sadeghlar, F; Sarria, GR; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T | 1 |
| Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S | 1 |
| Fujiwara, T; Hashimoto, M; Kunitomo, T; Maeda, N; Nishiwaki, N; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S | 1 |
| Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M | 3 |
| Chen, J; Chen, Y; Lin, YT; Liu, TX; Wang, C | 1 |
| Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y | 1 |
| Gabata, T; Kozaka, K; Sai, Y; Takamatsu, A; Toshima, F; Yamamoto, N; Yoshida, K | 1 |
| Akita, H; Fujii, Y; Hara, H; Haraguchi, N; Hasegawa, S; Kanemura, T; Matsuda, C; Mikamori, M; Miyata, H; Mukai, Y; Nishimura, J; Omori, T; Shinno, N; Sugase, T; Sugimura, K; Takeoka, T; Wada, H; Yamamoto, M; Yasui, M | 1 |
| Chan, KK; Chan, SY; Chan, WL; Cheung, EE; Choi, CW; Kwong, D; Lam, AT; Lam, KO; Law, BT; Law, S; Tsang, TH; Tse, RP; Wong, C; Wong, IY | 1 |
| Jia, SJ; Liu, Q; Song, LY; Wang, C; Zeng, H; Zeng, X | 1 |
| Chin, K; Doki, Y; Fujitani, K; Fushiki, K; Hironaka, S; Kato, K; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Okuno, T; Seki, S; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T | 1 |
| Inagaki, T; Kin, M; Kogo, M; Murakami, M; Otsuka, K; Sato, M | 1 |
| Chiba, Y; Haratani, K; Hayashi, H; Kanemura, H; Kawakami, H; Mitani, S; Nakagawa, K; Shiraishi, O; Suzuki, S; Yasuda, T; Yonesaka, K | 1 |
| Amanuma, Y; Arimitsu, Y; Chin, K; Kadowaki, S; Kanda, M; Kimura, Y; Kitagawa, Y; Kubota, Y; Nogi, Y; Okada, M; Takahashi, M; Yamamoto, S | 1 |
| Daiko, H; Honma, Y; Ishiyama, K; Kanematsu, K; Kato, K; Kubo, K; Kurita, D; Oguma, J; Utsunomiya, D; Yamamoto, S | 1 |
| Hiraki, Y; Imano, M; Kato, H; Momose, K; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T | 1 |
| Akimoto, S; Fujita, M; Goto, A; Inaba, K; Matsuoka, H; Nakamura, K; Nakauchi, M; Serizawa, A; Shibasaki, S; Suda, K; Tanaka, T; Umeki, Y; Uyama, I | 1 |
| Kawasaki, K; Nara, K; Sato, Y; Seto, Y; Suzuki, H; Takada, T; Toriumi, T; Yagi, K; Yamamoto, T | 1 |
| Bruckner, T; Büchler, MW; Crnovrsanin, N; Haag, GM; Jung, JO; Müller-Stich, BP; Nienhueser, H; Schiefer, S; Schmidt, T; Schneider, M; Sisic, L | 1 |
| Ebata, T; Fukaya, M; Miyata, K; Shimizu, D; Sugita, S | 1 |
| Ihara, K; Inoue, N; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T | 1 |
| Haruki, S; Miura, A; Sasaki, N; Suzuki, K; Yamaguchi, K | 1 |
| Eto, K; Kurogochi, T; Matsumoto, A; Nakayoshi, T; Nyumura, Y; Okamoto, T; Tanishima, Y; Yano, F | 1 |
| Hirabayashi, T; Kushida, S; Miki, I; Mimura, T; Nishikawa, M; Takegawa, N; Tanaka, S; Tokuyama, N; Tsuda, M; Tsumura, H; Yamamoto, Y | 1 |
| Mehta, R; Shariff, B | 1 |
| Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y | 1 |
| Daiko, H; Hara, H; Hori, K; Kadota, T; Kato, K; Kitagawa, Y; Mizusawa, J; Ogata, T; Ogawa, H; Sakamoto, T; Sakanaka, K; Terada, M | 1 |
| Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M | 1 |
| Asukai, K; Hasegawa, S; Miyata, H; Motoori, M; Nishimura, J; Ohue, M; Omori, T; Shinno, N; Sugimura, K; Takahashi, H; Takahashi, Y; Ushigome, H; Wada, H; Yamada, D; Yamamoto, K; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Kawamoto, T; Kosugi, Y; Oshima, M; Sasai, K; Shikama, N; Tsurumaru, M | 1 |
| Arai, K; Fujinaka, R; Kakinoki, K; Kuroda, D; Mani, M; Mii, Y; Murata, K; Oka, S; Okamoto, S; Otowa, Y | 1 |
| Ajani, JA; Amini, A; Barsoumian, HB; Bhutani, MS; Blum, MA; Chang, JY; Chen, D; Erasmus, JJ; Gomez, DR; Hess, KR; Hofstetter, WL; Lee, JH; Menon, H; Minsky, BD; Nguyen, QN; Seyedin, SN; Swisher, SG; Verma, V; Welsh, JW; Younes, AI | 1 |
| Dohi, O; Fujiwara, H; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Okayama, T; Shiozaki, A; Takagi, T; Teramukai, S; Uchiyama, K; Yasuda, T; Yoshida, N | 1 |
| Bugano, DDG; Maluf, FC; Rother, ET; Santos, VM; Uson Junior, PLS; Victor, EDS | 1 |
| Hamasu, S; Ikeda, Y; Konishi, S; Kudo, R; Manaka, D; Nishitai, R; Ota, T | 1 |
| Calomino, N; Cherri, S; Farsi, M; Fiaschi, AI; Francini, E; Francini, G; Marrelli, D; Miano, ST; Petrioli, R; Rovello, F; Savelli, V; Vernillo, R | 1 |
| Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S | 1 |
| Herrmann, K; Lordick, F | 1 |
| Ackland, SP; Barbour, AP; Barnes, EH; Burge, M; Falk, GL; Finch, R; Gebski, V; Karapetis, CS; Lampe, G; Mai, GT; Martin, JM; Marx, G; Nott, LM; Oostendorp, M; Shannon, J; Simes, J; Smithers, BM; Thomas, J; Varma, S; Walpole, ET; Watson, DI; Wilson, K; Zalcberg, JR | 1 |
| Hui, H; Sun, Y; Wei, B; Wu, J; Xu, L | 1 |
| Hanyu, T; Hirose, Y; Ichikawa, H; Ishikawa, T; Kameyama, H; Kano, Y; Kobayashi, T; Miura, K; Motegi, D; Nagahashi, M; Sakai, T; Sakata, J; Shimada, Y; Usui, K; Wakai, T | 1 |
| Kawamoto, T; Mine, S; Sasai, K; Shikama, N; Tsurumaru, M | 1 |
| Ajani, JA; Bhutani, MS; Huo, L; Jin, J; Johnson, RL; Lee, JH; Li, Y; Ma, L; Pool Pizzi, M; Scott, AW; Shanbhag, ND; Song, S; Wang, Y; Weston, B; Xu, Y | 1 |
| Chen, Y; Deng, J; Liu, Q; Xia, Y; Zhang, J; Zhao, K | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Abe, T; Aoki, K; Daiko, H; Hara, H; Kato, K; Kitagawa, Y; Kitano, S; Kojima, T; Mizoguchi, Y; Nagashima, K; Shiba, S; Tsubosa, Y; Yachida, S; Yamamoto, S | 1 |
| Baba, Y; Egashira, A; Emi, Y; Fujiwara, M; Iwata, N; Jogo, T; Kamori, T; Kawazoe, T; Kimura, Y; Makiyama, A; Mori, M; Morita, M; Nakaji, Y; Nakamura, T; Nakanoko, T; Nakashima, Y; Oki, E; Saeki, H; Shibata, T; Shimokawa, M; Tanaka, Y; Tokunaga, S; Zaitsu, Y | 1 |
| Adachi, T; Eguchi, S; Hidaka, M; Inoue, Y; Isagawa, Y; Ito, S; Kanetaka, K; Kawaguchi, Y; Kobayashi, K; Kobayashi, S; Kosaka, T; Kuba, S; Maruya, Y; Migita, K; Morita, M; Okada, S; Takatsuki, M; Torashima, Y; Yamaguchi, S; Yoneda, A; Yoshimoto, T | 1 |
| Abraham, P; Gricar, J; Shankaran, V; Zhang, Y | 1 |
| Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC | 1 |
| Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Matsuzawa, H; Mochizuki, N; Nomura, H; Tsuji, D; Yano, T | 1 |
| Abe, T; Bando, H; Higaki, E; Hosoi, T; Kadowaki, S; Muro, K; Nagao, T; Niwa, Y; Shimizu, Y; Tajika, M; Tanaka, T | 1 |
| Arakawa, Y; Matsumoto, A; Mitsumori, N; Nishikawa, K; Tanaka, Y; Tanishima, Y; Yanaga, K; Yuda, M | 1 |
| Adenis, A; Al-Rajabi, R; Bennouna, J; Bhagia, P; Chen, J; de la Fouchardiere, C; Doi, T; Enzinger, P; Ferreira, P; Francois, E; Girotto, G; Hsu, CH; Kang, SP; Kato, K; Kim, SB; Kojima, T; Lee, SH; Lordick, F; Metges, JP; Moriwaki, T; Muro, K; Qin, SK; Senellart, H; Shah, MA; Shen, L; Suryawanshi, S; Wang, R | 1 |
| Alesina, P; Bartsch, D; Függer, R; Furrer, M; Gérard, MA; Gloor, B; Grieder, F; Hawle, H; Hayoz, S; Kettelhack, C; Knoefel, WT; Köigsrainer, A; Marti, WR; Piessen, G; Ruhstaller, T; Schäfer, M; Schmidt, S; Schnider, A; Steffen, T; von Holzen, U; Walz, MK | 1 |
| Deng, L; Feng, L; Guo, R; Li, Y; Liu, Z; Qin, L; Yu, Z; Zheng, Y; Zhu, X | 1 |
| Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A | 1 |
| Chang Lee, R; Hsieh, AH; Moldovan, M; Price, T; Tomita, Y; Townsend, A | 1 |
| Cai, B; Di, X; Ge, X; Liu, Z; Sun, X; Xia, X | 1 |
| Ajani, JA; Bhutani, M; Chen, Q; Correa, A; Estrella, JS; Gan, B; Hofstetter, WL; Huo, L; Jin, J; Johnson, RL; Lee, JH; Lei, G; Li, CY; Li, Y; Liu, B; Ma, L; Pizzi, MP; Scott, A; Shanbhag, N; Song, S; Wang, Y; Wei, S; Weston, B; Xiao, L | 1 |
| Gao, Y; Jiang, C; Wang, T; Wei, B; Wu, J; Zhou, Y | 1 |
| Engel, J; Fagbemi, SO; Li, YH; Onitilo, AA; Shiyanbola, O; Stankowski-Drengler, TJ; Tanimu, S | 1 |
| Chen, Y; Gou, H; Hu, J; Leng, W; Ni, L; Qiu, M; Zhang, W | 1 |
| Cai, L; Hu, Y; Li, Q; Liu, H; Liu, M; Liu, S; Luo, L; Qiu, B; Shen, J; Xi, M; Yang, Y; Zhang, L; Zhao, L; Zhu, Y | 1 |
| Chen, W; Gu, D; Lu, J; Tao, H; Yao, C; Zhou, Y | 1 |
| Antoun, J; Arej, N; Chelala, E; El Karak, F; Farhat, F; Haddad, FG; Kattan, J; Kourie, HR; Zaarour, K | 1 |
| Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T | 1 |
| Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P | 1 |
| Bruns, CJ; Schröder, W | 1 |
| Akita, H; Fujiwara, Y; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Ohue, M; Omori, T; Sugimura, K; Takahashi, H; Tomokuni, A; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Ding, XZ; Gao, SG; Hu, XC; Izumiya, Y; Kong, DJ; Lam, KS; Li, XC; Li, YP; Lin, TY; Wang, XS; Yang, JQ; Zhang, L | 1 |
| Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Al, MJ; Armstrong, N; Blommestein, HM; Büyükkaramikli, NC; Clay, FJ; Kleijnen, J; Riemsma, R; Ross, J; Severens, J; Worthy, G | 1 |
| Akiyama, Y; Chiba, T; Endo, F; Iwaya, T; Kimura, Y; Koeda, K; Mizuno, M; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T | 1 |
| Ito, M; Kitano, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakatani, M; Obayashi, C; Sho, M; Takano, M; Wakatsuki, K | 1 |
| Hamamoto, Y; Ito, Y; Kato, H; Kato, K; Kitagawa, Y; Kuroki, Y; Miyata, Y; Nozaki, I; Ogawa, H; Sato, H; Tsubosa, Y; Yasuda, T; Yokota, T | 1 |
| Du, N; Li, X; Liang, R; Liu, J; Pang, Y; Ren, H; Sun, X; Tang, SC; Xu, C; Zhang, B; Zhang, J; Zhang, Y | 1 |
| Etoh, T; Fujishima, H; Fumoto, S; Inomata, M; Moriyama, M; Nishiki, K; Shibata, T; Shiraishi, N; Tsukamoto, Y | 1 |
| Cartwright, E; Cunningham, D | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Wada, N; Yamasaki, M | 1 |
| Ihara, K; Kato, H; Kikuchi, M; Kurayama, E; Kuwano, H; Miyazaki, T; Muroi, H; Nakajima, M; Ogata, H; Sakai, M; Sasaki, K; Shida, Y; Sohda, M; Takahashi, M; Yamaguchi, S | 1 |
| Fujiwara, T; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Noma, K; Shirakawa, Y; Tanabe, S | 1 |
| Hiwatashi, K; Maenohara, S; Minami, K; Natsugoe, S; Okumura, H; Omoto, I; Sasaki, K; Setoyama, T; Tsuruda, Y; Uchikado, Y | 1 |
| Kobayashi, K; Miki, H; Okada, K; Takeoka, T | 1 |
| Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Naito, A; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Arita, T; Fujiwara, H; Hikami, S; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Odagiri, K; Takahashi, T; Tanaka, K; Yamazaki, M | 1 |
| Carter, BW; Goense, L; Ho, L; Hofstetter, WL; Lin, SH; Maru, DM; Meijer, GJ; van Hillegersberg, R; van Rossum, PSN; Xi, M | 1 |
| Bedenne, L; Bitzer, M; Brauchli, P; Budach, W; Eisterer, W; Girschikofsky, M; Hawle, H; Hayoz, S; Hess, V; Knorrenschild, JR; Mariette, C; Mingrone, W; Montemurro, M; Plasswilm, L; Ruhstaller, T; Schacher, S; Schmidt, SC; Schnider, A; Stahl, M; Thuss-Patience, P | 1 |
| Arava, S; Gogia, A; Kumar, R; Kumar, S; Tripathi, M | 1 |
| Hayata, K; Katsuda, M; Maruoka, S; Nakamori, M; Nakamura, M; Ojima, T; Shimokawa, T; Yamaue, H | 1 |
| Cannita, K; Cortellini, A; De Berardis, B; Ficorella, C; Lanfiuti Baldi, P; Parisi, A; Porzio, G; Venditti, O; Verna, L; Vicentini, R; Vicentini, V | 1 |
| Heishi, T; Ishida, H; Ito, K; Kamei, T; Konno-Kumagai, T; Maruyama, S; Okamoto, H; Onodera, Y; Sakurai, T; Sato, C; Taniyama, Y; Teshima, J | 1 |
| Akiyama, Y; Amano, S; Baba, S; Chiba, T; Endo, F; Iwaya, T; Kimura, T; Kimura, Y; Koeda, K; Mizuno, M; Nikai, H; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T; Umemura, A | 1 |
| Ding, XZ; Gao, SG; He, Y; Hu, XC; Kong, DJ; Li, XC; Li, Y; Lin, TY; Wang, XS; Yang, JQ; Zhang, L; Zhao, MQ | 1 |
| Baatar, S; Gombodorj, N; Kumakura, Y; Kuriyama, K; Kuwano, H; Miyazaki, T; Nishiyama, M; Sakai, M; Shirabe, K; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T; Yoshida, T | 1 |
| Aoki, M; Komori, K; Sandou, M; Takagi, M; Uejima, E; Yoshida, Y | 1 |
| Dohi, O; Doi, T; Fujiwara, H; Handa, O; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Ohta, T; Okayama, T; Shiozaki, A; Takagi, T; Uchiyama, K; Yasuda, T; Yoshida, J; Yoshida, N | 1 |
| Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Terai, S; Yamaguchi, T | 1 |
| Hu, Y; Huang, C; Li, Q; Liu, H; Liu, M; Yuan, Y; Zhang, W; Zhu, Y | 1 |
| Chikugo, T; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kawakami, H; Kimura, Y; Nakagawa, K; Okuno, T; Shinkai, M; Shiraishi, O; Ueda, H; Yasuda, A; Yasuda, T | 1 |
| Fushida, S; Gabata, R; Gunjigake, K; Ninomiya, I; Ohta, T; Okamoto, K; Yamaguchi, T | 1 |
| Fukuda, K; Irino, T; Kawakubo, H; Kitagawa, Y; Mayanagi, S; Nakamura, R; Takeuchi, H; Takeuchi, M; Wada, N; Yoshida, K | 1 |
| Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M | 1 |
| Baba, H; Baba, Y; Harada, K; Imai, K; Imamura, Y; Ishimoto, T; Iwatsuki, M; Karashima, R; Koga, Y; Nagai, Y; Nomoto, D; Okadome, K; Watanabe, M; Yoshida, N | 1 |
| Dohi, O; Doi, T; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Okayama, T; Ota, T; Sakamoto, N; Takagi, T; Uchiyama, K; Yasuda, T; Yoshida, J; Yoshida, N | 1 |
| Kazuno, A; Koyanagi, K; Ninomiya, Y; Oguma, J; Ozawa, S; Yamamoto, M; Yatabe, K | 1 |
| Cao, F; Chen, X; Cheng, J; Er, P; Guan, Y; Jiang, H; Li, X; Pang, Q; Qian, D; Wang, J; Wang, P; Wang, Y; Yu, Z; Yuan, Z; Zhang, B; Zhang, W; Zhao, G; Zhou, D | 1 |
| Akiyama, Y; Baba, S; Chiba, T; Endo, F; Iwaya, T; Kimura, T; Kimura, Y; Koeda, K; Mizuno, M; Nikai, H; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T | 1 |
| Ohkura, Y; Udagawa, H; Ueno, M | 1 |
| Daiko, H; Hatogai, K; Kawasaki, T; Kojima, T; Maki, Y; Mochizuki, N; Nomura, H; Saito, S; Tanaka, M | 1 |
| Akutsu, Y; Chin, K; Hamamoto, Y; Hara, H; Hironaka, S; Ito, Y; Kato, K; Kawakami, K; Kii, T; Kitagawa, Y; Kojima, T; Kojima, Y; Makiuchi, T; Matsushita, H; Mori, K; Nagumo, R; Ogawa, H; Tsubosa, Y; Ura, T; Yokota, T | 1 |
| Cardic, MB; Chao, Y; Chen, LT; Cunningham, D; de Gramont, A; Kang, YK; Kujundzic, M; Lim, HY; Park, SR; Ramos, FJ; Rees, C; Roy, AC; Tabernero, J; Yeh, CG | 1 |
| Akutsu, Y; Hoshino, I; Kono, T; Matsubara, H; Miyazawa, Y; Shiratori, T; Shuto, K; Takeshita, N; Uesato, M | 1 |
| Dobrovic, A; Ganju, V; Gebski, VJ; Mellor, D; Parry, MM; Pavlakis, N; Strickland, AH; Tebbutt, NC; Van Hazel, GA; Zannino, D | 1 |
| Al-Batran, SE; Hartmann, JT; Hofheinz, RD; Homann, N; Kripp, M; Moehler, M; Pauligk, C; Rosowski, J | 1 |
| Huang, XE; Liu, J; Lu, YY; Shen, K; Wu, XY; Xiang, J | 1 |
| Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P | 1 |
| Ando, N; Daiko, H; Fukuda, H; Hironaka, S; Igaki, H; Ito, Y; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Tsubosa, Y; Udagawa, H | 1 |
| Asmar, L; Cohn, A; David McCollum, A; Diab, S; Hecker, LI; Kocs, DM; Richards, D; Spira, AI; Zhan, F | 1 |
| Jeong, S; Ki, SH; Kim, HG; Kwon, KS; Lee, DH; Lee, JI; Park, IS; Shin, YW | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Sugimura, K; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M | 1 |
| Fujiwara, H; Furukawa, T; Furukita, Y; Goto, M; Ikeda, M; Morimoto, M; Nishino, T; Seike, J; Takechi, H; Tangoku, A; Yamamoto, Y | 1 |
| Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH | 1 |
| Arita, K; Bhunachet, E; Haruki, S; Hiranuma, S; Ito, K; Matsumoto, A; Takiguchi, N; Usui, S | 1 |
| Daiko, H; Hamamoto, Y; Hara, H; Hosoya, Y; Igaki, H; Kadowaki, S; Kato, K; Matsushita, H; Nagase, M; Tahara, M; Tanaka, Y | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| Arnold, D; Geissler, M; Grothe, W; Hofheinz, RD; Moehler, M; Reinacher-Schick, A; Schmoll, HJ; Seufferlein, T; Stein, A; Thuss-Patience, PC | 1 |
| Ji, FZ; Li, T; Pan, P; Tao, GZ; Yu, CH; Zhou, XL; Zhu, WG | 1 |
| Li, X; Lin, S; Lin, W; Lin, Y; Wang, H | 1 |
| Arena, MG; Barba, M; Belli, F; Di Lauro, L; Fattoruso, SI; Giannarelli, D; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Mihara, H; Minemura, M; Nishikawa, J; Ogawa, K; Sugiyama, T; Ueda, A; Ueda, Y; Yoshita, H | 1 |
| Park, SH | 1 |
| Blazeby, JM; Bridgewater, JA; Chau, I; Cook, N; Coxon, FY; Cunningham, D; Dunn, JA; Falk, S; Ford, HE; Fyfe, D; Janowitz, T; Kareclas, P; Madhusudan, S; Mansoor, W; Marshall, A; Middleton, GW; Swinson, D; Wadsley, J | 1 |
| Fujiwara, T; Katsube, R; Maeda, N; Noma, K; Ohara, T; Sakurama, K; Shirakawa, Y; Tanabe, S | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Nishiya, S; Okubo, Y; Sato, S | 1 |
| Asaka, S; Endo, M; Katsube, T; Miyaki, A; Murayama, M; Naitou, E; Naritaka, Y; Shimakawa, T; Shimazaki, A; Shiozawa, S; Usuda, A; Yamaguchi, K; Yokomizo, H; Yoshimatsu, K | 1 |
| Gonda, T; Halmos, B; Melamed, J; Miller, G; Rotterdam, H; Seetharamu, N; Villanueva, G | 1 |
| Battafarano, RJ; Burrows, WM; Edelman, MJ; Hanlon, AL; Horiba, MN; Kim, GJ; Koshy, M; Suntharalingam, M | 1 |
| Ban, X; Cai, Z; Cao, TT; Chen, J; Fu, L; Guan, XY; Huang, P; Li, JB; Li, Y; Qian, C; Qin, Y; Xie, D; Zeng, TT; Zeng, ZL; Zhou, J | 1 |
| Cassivi, SD; Decker, PA; Ferguson, MK; Lockhart, AC; Meyers, BF; Montero, AJ; Oeltjen, AR; Putnam, JB; Reed, CE; Schefter, TE | 1 |
| Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N | 1 |
| Cha, J; Kim, SK; Koom, WS; Lee, CG; Lee, IJ; Lee, JY; Suh, YG | 1 |
| Baba, H; Baba, Y; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Karashima, R; Miyamoto, Y; Sakamoto, Y; Watanabe, M; Yoshida, N | 1 |
| Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S | 1 |
| Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J | 1 |
| Haruma, K; Higashida, M; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Nakamura, M; Yoden, E | 1 |
| Ades, S; Alcindor, T; Aloraini, A; Asselah, J; Brisson, S; David, M; Ferri, L; Frechette, D; Sudarshan, M; Thirlwell, M; van Huyse, M | 1 |
| Cai, XY; Chen, XX; Guo, GF; He, WZ; Jiang, C; Liao, FX; Qiu, HJ; Rong, YM; Xia, LP; Yang, Q; Yin, CX; Zhang, B | 1 |
| Chin, K; Doki, Y; Fujitani, K; Hironaka, S; Kato, K; Kii, T; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Nakamura, T; Okuno, T; Seki, S; Taira, K; Taniki, T; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T | 1 |
| Jambhekar, N; Jandyal, S; Joshi, A; Noronha, V; Prabhash, K | 1 |
| Deng, WY; Li, N; Li, X; Luo, SX; Song, T | 1 |
| Huang, ZJ; Lin, JQ; Xu, TW; Yang, N | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 2 |
| Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Di, ZL; Ke, Y; Ma, HB; Ren, J; Sun, X; Wen, J | 1 |
| Alcindor, T; Asselah, J; Cools-Lartigue, J; Eckert, E; Ferri, LE; Jones, D; Rousseau, M; Spicer, J; Vanhuyse, M; Zourikian, T | 1 |
| Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T | 2 |
| Hosoda, K; Katada, N; Kikuchi, S; Mieno, H; Moriya, H; Sakuramoto, S; Watanabe, M; Yamashita, K | 1 |
| Domeki, Y; Kato, H; Murakami, M; Muroi, H; Nakajima, M; Nakamura, T; Satomura, H; Takada, A; Takahashi, M | 1 |
| Chin, K; Fukuda, H; Hironaka, S; Kataoka, K; Katayama, H; Kato, K; Kii, T; Kitagawa, Y; Mizusawa, J; Shibuya, Y; Tsubosa, Y; Tsushima, T | 1 |
| Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T | 1 |
| Fujita, H; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Miura, S; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Ohno, Y; Tomita, Y; Ueda, N | 1 |
| Bianco, V; Brozzetti, S; Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Rossi, G; Roviello, F; Roviello, G | 1 |
| Fujimura, T; Kitagawa, H; Makino, I; Maruzen, S; Nakamura, K; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Takamura, H | 1 |
| Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY | 1 |
| Emi, M; Hamai, Y; Hihara, J; Kenjo, M; Murakami, Y; Nagata, Y; Okada, M | 1 |
| Chen, X; Gao, Y; Han, Q; Jin, Y; Qian, Z; Wan, L; Wei, B; Wu, J; Xu, L; Zhang, X; Zhou, J; Zhu, J | 1 |
| Choudhury, NR; Garg, S; Knott, R; Shaikh, M | 1 |
| Kawakami, H; Nakagawa, K; Nishina, S; Nonagase, Y; Okabe, T; Sakiyama, T; Tamura, T; Ueda, S | 1 |
| Abe, T; Andoh, M; Ishihara, M; Kadowaki, S; Kawai, R; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tajika, M; Tanaka, T; Taniguchi, H; Uemura, N; Ura, T | 1 |
| Han, S; Liang, H; Liu, W; Wen, H; Yang, H; Yao, J; Yu, L | 1 |
| Liu, MZ; Liu, SL; Luo, LL; Wu, YJ; Xi, M; Yang, H; Yang, YD; Zhang, P; Zhao, L | 1 |
| Hayashi, T; Hirakawa, M; Hori, M; Kato, J; Kobune, M; Miyanishi, K; Nakata, K; Ohnuma, H; Okagawa, Y; Osuga, T; Sagawa, T; Sakata, K; Sato, T; Sato, Y; Someya, M; Takayama, T; Takimoto, R | 1 |
| Bronsert, P; Glatz, T; Hoeppner, J; Hopt, UT; Kulemann, B; Makowiec, F; Marjanovic, G; Schäfer, M; Sick, O; Zirlik, K | 1 |
| Bencivenga, M; Carbone, C; De Manzoni, G; Frizziero, M; Giacopuzzi, S; Melisi, D; Merz, V; Mina, MM; Piro, G; Santoro, R; Tortora, G; Verlato, G; Zanoni, A; Zanotto, M | 1 |
| Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y | 1 |
| Dunn, JA; Ford, HE; Hulme, CT; Marshall, A; Meads, DM | 1 |
| Domeki, Y; Ihara, K; Kato, H; Kikuchi, M; Kubo, T; Muroi, H; Nakajima, M; Otomo, H; Sasaki, K; Satomura, H; Takahashi, M; Yamaguchi, S | 1 |
| Aga, K; Harada, H; Kaburagi, T; Koizumi, W; Matsumoto, H; Sakata, M; Seki, H; Shimada, A; Watanabe, H; Yasui, N | 1 |
| Hayashi, T; Horii, N; Inoue, H; Kimura, J; Kunisaki, C; Maezawa, Y; Makino, H; Masuda, M; Ohnishi, H; Ohshima, T; Rino, Y; Suzuki, Y; Takagawa, R; Tsuburaya, A; Yamamoto, J | 1 |
| Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Legdeur, MC; Meulendijks, D; Schellens, JH | 1 |
| Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Baba, H; Baba, Y; Harada, K; Higashi, T; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Izumi, D; Kosumi, K; Miyamoto, Y; Miyata, T; Sakamoto, Y; Shiraishi, S; Taki, K; Tokunaga, R; Watanabe, M; Yamashita, Y; Yoshida, N | 1 |
| Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyanaga, S; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T | 1 |
| Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M; Yanagimoto, Y | 1 |
| Hayata, K; Iwahashi, M; Kato, T; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Tabata, H; Takeuchi, A; Yamaue, H | 1 |
| Cooray, P; Ferraro, DA; Ganju, V; Gebski, V; Hall, M; Pavlakis, N; Price, TJ; Shannon, JA; Sjoquist, KM; Strickland, A; Tebbutt, NC; Underhill, C; Varma, SC; Veillard, AS; Wong, N; Young, R | 1 |
| Hoshi, K; Hosoda, K; Katada, C; Katada, N; Koizumi, W; Mieno, H; Moriya, H; Watanabe, M; Yamashita, K | 1 |
| Matsuhashi, N; Miyazaki, T; Okumura, N; Tanahashi, T; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K | 1 |
| Fukuchi, M; Inose, T; Kato, H; Kuwano, H; Masuda, N; Miyazaki, T; Nakajima, M; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N | 1 |
| Hara, K; Honjo, H; Kuwano, H; Miyazaki, T; Ozawa, D; Sakai, M; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T | 1 |
| Qin, RQ; Wang, WP; Wen, YS; Xi, KX; Yu, XY; Zhang, LJ | 1 |
| Cheng, Y; Guan, S; Huang, X; Jia, Y; Ma, Y; Song, Q; Sun, Y; Tan, B; Wang, C; Wang, J; Yao, B | 1 |
| Hoshino, S; Iwasaki, K; Osaka, Y; Ota, Y; Suda, T; Tachibana, S; Tsuchida, A | 1 |
| Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Chikamatsu, S; Imai, H; Ishioka, C; Kasahara, Y; Kobayashi, A; Komine, K; Oishi, T; Okada, Y; Okita, A; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F | 1 |
| Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Abe, T; Hazama, S; Kanekiyo, S; Kitahara, M; Michihisa, I; Nagano, H; Nakajima, M; Nishiyama, M; Shindou, Y; Takeda, S; Yoshino, S | 1 |
| Aiba, K; Arakawa, Y; Ishibashi, Y; Matsumoto, A; Mitsumori, N; Nishikawa, K; Omura, N; Sakuyama, T; Tanaka, Y; Tanishima, Y; Yanaga, K; Yuda, M | 1 |
| Daiko, H; Doi, T; Fujii, S; Fujita, T; Hatogai, K; Kadota, T; Kojima, T; Ohtsu, A; Takiguchi, Y; Yoshino, T | 1 |
| Hayata, K; Katsuda, M; Nakamori, M; Nakamura, M; Nakamura, Y; Ojima, T; Yamaue, H | 1 |
| Guo, X; Hu, YH; Li, QQ; Liu, H; Liu, MZ; Liu, Q; Liu, SL; Luo, LL; Xi, M; Zhang, P; Zhao, L | 1 |
| Bando, H; Chin, K; Hamauchi, S; Hara, H; Honma, Y; Iwasa, S; Kato, K; Kii, T; Kiyota, N; Kojima, T; Mochizuki, S; Ohtsu, A; Satake, H; Tahara, M; Tsushima, T; Yamazaki, T; Yokota, T; Zenda, S | 1 |
| Al-Fakeeh, A; Al-Ruzug, I; Alcindor, T; Doerksen, T; Ferri, L; Mulla, N; Santos, F | 1 |
| Abramovich, A; Amit, L; Brenner, B; Gordon, N; Idelevich, E; Kundel, Y; Medalia, G; Purim, O; Sadeh Gonik, U; Sarfaty, M; Sulkes, A | 1 |
| Bonnetain, F; Borg, C; Cléau, D; Fein, F; Fiteni, F; Foubert, A; Fratté, S; Jacquin, M; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Mariette, C; Mathieu, P; Messager, M; Nguyen, T; Paget-Bailly, S; Sakek, N | 1 |
| Ambrosi, E; Casella, F; de Manzoni, G; Di Leo, A; Giacopuzzi, S; Motton, M; Ricci, F; Rice, TW; Vassiliadis, A; Verlato, G; Weindelmayer, J; Zanoni, A | 1 |
| Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N | 1 |
| Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Bitzer, M; Bösmüller, H; Clasen, S; Götz, M; Häussler, U; Malek, NP; Plentz, RR | 1 |
| Cho, H; Hayashi, T; Ikeda, K; Kano, K; Maezawa, Y; Masuda, M; Nakajima, T; Ogata, T; Ohshima, T; Rino, Y; Sato, T; Segami, K; Yamada, T; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Cheng, SY; Du, J; Li, J; Li, KC | 1 |
| Liang, N; Luo, H; Qiao, L; Xie, J; Yu, X; Zhang, J | 1 |
| Akutsu, Y; Asami, C; Chin, K; Hamamoto, Y; Hara, H; Hironaka, S; Ito, Y; Kato, K; Kawakami, K; Kii, T; Kitagawa, Y; Kojima, T; Kojima, Y; Matsushita, H; Mori, K; Nagai, Y; Ogawa, H; Tsubosa, Y; Ura, T; Yokota, T | 1 |
| Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Motoori, M; Shinkai, M; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Hosoda, K; Katada, C; Katada, N; Komori, S; Mieno, H; Moriya, H; Sugawara, M; Watanabe, M; Yamashita, K | 1 |
| Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R | 1 |
| Hatanaka, N; Hirao, T; Iwamoto, K; Kono, E; Mizuno, H; Morimoto, Y; Noro, H; Son, C; Takaichi, S; Yamasaki, Y; Yasumasa, K | 1 |
| Feng, X; Gao, C; Liu, L; Qu, D; Shi, F; Su, X; Wang, C | 1 |
| Aizawa, M; Bamba, T; Homma, K; Katsumi, C; Matsuki, A; Nakagawa, S; Yabusaki, H | 1 |
| Abou, M; Cacheux, W; Fernandez, E; Frossard, JL; Huber, O; Koessler, T; Moniez, M; Puppa, G; Roth, A | 1 |
| Cai, R; Dai, M; Diao, D; Ding, Y; Dong, X; Han, Z; Jia, C; Li, J; Shan, L; Su, Y; Wang, L; Xiong, G; Xu, W; Zheng, H; Zhou, L | 1 |
| Kitamura, S; Kuga, Y; Miwata, T; Mouri, T; Nishida, T; Sakimoto, H | 1 |
| Kajiyama, Y; Okumura, K; Okumura, M; Takeda, K; Tsurumaru, M | 1 |
| Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J | 1 |
| Ehara, K; Kinoshita, Y; Mine, S; Tsutsumi, K; Udagawa, H; Ueno, M | 1 |
| Kubo, A; Mitsui, Y; Nakahara, T; Shigematsu, N; Takagi, Y; Takemasa, K; Tsuyuki, A | 1 |
| Fujita, Y; Hiramatsu, M; Kawai, M; Nishimura, H; Sumiyoshi, K; Tanigawa, N | 1 |
| Fujii, Y; Harata, K; Ishiguro, H; Katada, T; Kimura, M; Kuwabara, Y; Mitsui, A; Mori, R; Mori, Y; Ogawa, R; Tomoda, K | 1 |
| Nishimura, T; Oka, M; Takeda, S; Tokunou, K; Yoshino, S | 1 |
| Blaszkowsky, LS; Clark, JW; Earle, CC; Enzinger, PC; Fidias, P; Fuchs, CS; Kulke, MH; Mayer, RJ; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Vincitore, MM; Zhu, AX | 1 |
| Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S | 1 |
| Arai, H; Kobayashi, Y; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Nishi, Y; Sasajima, K; Sugiura, A; Suzuki, S; Tajiri, T; Wakabayashi, H; Yanagi, K; Yokoyama, T | 1 |
| BalmerMajno, S; Bodis, S; Borner, M; Hess, V; Köberle, D; Mingrone, W; Pestalozzi, BC; Popescu, R; Roth, A; Ruhstaller, T; Schnider, A; Schuller, JC; Terraciano, L; von Moos, R; Widmer, L | 1 |
| Cao, Z; Jin, J; Li, X; Liu, J; Lu, W; Tucker, SJ; Wang, D; Wang, F; Xu, X; Yan, G; Zhong, B | 1 |
| Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T | 1 |
| He, ZY; Hu, YH; Li, QQ; Lin, HX; Liu, H; Liu, MZ | 1 |
| Bae, SH; Baek, JH; Do, YR; Kim, JY; Kim, MK; Lee, KH; Park, KU; Ryoo, HM; Song, HS | 1 |
| Artale, S; Bardelli, A; Barone, C; Cascinu, S; Di Fabio, F; Falcone, A; Giannetta, L; Giaquinta, S; Martoni, AA; Mutri, V; Pinto, C; Rojas Llimpe, FL; Schinzari, G; Siena, S; Stella, G | 1 |
| Arimura, Y; Hokari, K; Hosokawa, M; Kodaira, J; Okahara, S; Shinomura, Y; Takahashi, H; Tanuma, T; Tsukagoshi, H; Yamashita, K | 1 |
| Fujiwara, H; Ikoma, H; Kikuchi, S; Kokuba, Y; Kubota, T; Nakanishi, M; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Sakakura, C; Sonoyama, T; Suchi, K; Todo, M; Umehara, S | 1 |
| Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Kaida, Y; Kubota, H; Matsumoto, H; Murakami, H; Oka, Y; Okumura, H; Saito, A; Uragami, A; Yamashita, K; Yoden, E | 1 |
| Cummins, MM; Ganju, V; Gebski, V; Gibbs, D; Sourjina, T; Stockler, M; Strickland, A; Tebbutt, NC; Van Hazel, G; Zalcberg, J | 1 |
| Abbruzzese, JL; Ajani, J; Ho, L; Jhamb, J; Kazmi, SM; Lin, E; Overman, MJ; Phan, A; Yao, JC | 1 |
| Bae, WK; Cho, SB; Cho, SH; Chung, IJ; Hwang, JE; Joo, YE; Lee, WS; Na, KJ; Shim, HJ; Song, SY | 1 |
| Asaka, S; Ide, H; Isohata, N; Katsube, T; Konno, S; Murayama, M; Naritaka, Y; Ogawa, K; Shimakawa, T; Yamaguchi, K | 1 |
| Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY | 1 |
| Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E | 1 |
| Bauerfeind, P; Bertschinger, P; Binek, J; Brauchli, P; Frossard, JL; Jost, C; Knuchel, J; Metzger, U; Meyenberger, C; Ruhstaller, T; Schuller, JC; Werth, B | 1 |
| Burris, HA; Clark, BL; Farley, C; Gray, JR; Greco, FA; Hainsworth, JD; Lane, CM; Meluch, AA; Spigel, DR | 1 |
| Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H | 1 |
| Andersen, M; Jensen, HA; Pfeiffer, P; Schønnemann, KR; Vestermark, LW; Yilmaz, M | 1 |
| Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M | 1 |
| Aggarwal, S; Goel, G; Jauhri, M; Negi, A | 1 |
| Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T | 1 |
| Allali, M; Bergmann, U; Kummer, G; Riebeling, J; Schultheis, B; Sendler, A; Sendler, U; Strumberg, D; Tannapfel, A | 1 |
| Hayashi, S; Karaki, H; Okaya, T; Sasaki, K; Sugano, I; Sugimoto, K; Suzuki, H; Yamamori, H; Yamamoto, K | 1 |
| Kito, F; Kunisaki, C; Matsuda, S; Mochizuki, Y; Takahashi, M; Watanabe, J; Yabuno, T | 1 |
| Ansari, RH; Choong, NW; Ferguson, MK; Fishkin, PA; Haraf, DC; Hoffman, PC; Kesler, KA; Kocherginsky, M; Krauss, SA; Mauer, AM; Posner, MC; Sandler, AB; Sciortino, DF; Szeto, L; Vokes, EE; Wade, J | 1 |
| Bernal, P; Byrd, J; Malik, I | 1 |
| Andersen, M; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
| Osada, S; Sanada, Y; Takahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Arai, H; Hirakata, A; Kawamoto, M; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Umakoshi, M; Wakabayashi, H; Yokoyama, T | 1 |
| de Vries, A; Gastl, G; Lukas, P; Mühlmann, G; Öfner, D; Pluschnig, U; Spizzo, G; Steger, G; Widder, J; Zabernigg, A; Zacherl, J | 1 |
| Day, FL; Di Iulio, J; Jefford, M; Leong, T; Matera, A; McKendick, J; Michael, M; Milner, AD; Ngan, S; Rischin, D; Thomas, R; Zalcberg, JR | 1 |
| Gu, XW; Pan, YK; Xu, X; Zhang, TR; Zhao, T | 1 |
| Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA | 1 |
| Brauchli, P; Dietrich, D; Gautschi, O; Hess, V; Inauen, R; Kranzbuehler, H; Mingrone, W; Montemurro, M; Moosmann, P; Pless, M; Rauch, D; Ruhstaller, T; Schneider, PM; von Moos, R; Widmer, L | 1 |
| Fujiwara, H; Furutani, A; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Shiozaki, A; Sonoyama, T; Todo, M; Umehara, S; Yoneda, M | 1 |
| Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Morimoto, J; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sakurai, K; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, Y; Kurokawa, T; Nagahama, T; Tei, S; Watayou, Y | 1 |
| Kanemura, T; Kobayashi, M; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Ono, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Uchiyama, C; Yanai, A; Yoshioka, Y | 1 |
| Hamatsu, T; Hasegawa, H; Honboh, T; Kabashima, A; Kitamura, M; Kudo, K; Ninomiya, M; Ushijima, C | 1 |
| Ardalan, B; Avisar, E; Franceschi, D; Lima, M; Livingstone, A; Mezentsev, D; Podolsky, L; Reis, I; Rios, J; Solomon, N | 1 |
| Baba, H; Baba, Y; Hayashi, N; Hirashima, K; Hiyoshi, Y; Imamura, Y; Iwagami, S; Iwatsuki, M; Karashima, R; Kinoshita, K; Kurashige, J; Miyamoto, Y; Nagai, Y; Saito, S; Sato, N; Watanabe, M | 1 |
| Chun, CL; Dormady, S; Eisenstat, S; Lombard, C; Triadafilopoulos, G | 1 |
| Ashley, S; Charalambous, H; Chau, I; Cunningham, D; Hawkes, E; Koukouma, A; Okines, AF; Papamichael, D; Rao, S | 1 |
| Aoki, T; Hoshino, S; Ogata, T; Osaka, Y; Shinohara, M; Takagi, Y; Tsuchida, A | 1 |
| Ehara, K; Hasebe, S; Hayashi, M; Ito, T; Kinoshita, Y; Minowa, M; Ogawa, M; Takebayashi, K; Udagawa, H; Ueno, M | 1 |
| Arai, H; Hirakata, A; Kawamoto, M; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Umakoshi, M; Wakabayashi, H; Yokoyama, T; Yoshida, H | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Hedman, H; Henriksson, R; Hesselius, P; Lennartsson, J; Wu, X | 1 |
| Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T | 1 |
| Cui, N; Hao, Y; Hu, Y; Liu, H; Liu, M; Lu, L; Mo, Y; Rong, T; Zhu, Q | 1 |
| Brugarolas, A; Pérez, T; Pérez-Ruixo, JJ; Rebollo, J; Valenzuela, B | 1 |
| Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J | 1 |
| Fan, X; Guo, B; Guo, W; Jiang, Y; Li, K; Liang, S; Qin, S; Wang, L; Wang, R; Zhao, Y | 1 |
| Lin, XD; Shi, XY; Zhang, WJ; Zhou, TC | 1 |
| Barthelemy, N; Chin, SH; Cunningham, JE; Falkowski, P; Kelechi, T; Sterba, K | 1 |
| Aizawa, T; Fujiwara, S; Harada, K; Kubo, N; Noguchi, T | 1 |
| Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Furukita, Y; Ikeda, M; Minato, T; Seike, J; Takashima, M; Takechi, H; Tangoku, A; Yamamoto, Y | 1 |
| Bonetti, A; Durante, E; Mercanti, A; Piacentini, P; Trolese, A | 1 |
| Bando, Y; Furukita, Y; Kajiura, K; Minato, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yamamoto, Y; Yoshida, T | 1 |
| Abe, T; Hatooka, S; Kondo, C; Mizota, A; Muro, K; Nomura, M; Shinoda, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T | 1 |
| Bayraktar, S; Bayraktar, UD; Chen, E; Hosein, P; Koniaris, LG; Montero, AJ; Rocha-Lima, CM | 1 |
| Ades, S; Alcindor, T; Artho, G; Chasen, M; Ferri, LE; Hickeson, M; Marcus, V; Thirlwell, MP | 1 |
| Ariga, H; Jingu, K; Koto, M; Kubozono, M; Miyata, G; Narazaki, K; Nemoto, K; Onodera, K; Sugawara, T; Takeda, K; Umezawa, R; Yamada, S | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T | 1 |
| Stravodimou, A; Voutsadakis, IA | 1 |
| Bechter, O; DE Vries, A; Eisterer, W; Kendler, D; Königsrainer, A; Lukas, P; Nehoda, H; Ofner, D; Spechtenhauser, B; Virgolini, I; Wöll, E | 1 |
| Osada, S; Takahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Egawa, T; Eto, E; Inaba, Y; Irino, T; Ito, Y; Kenmochi, T; Mihara, K; Murakawa, M; Nagashima, A; Okamura, A | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Yoneda, M | 1 |
| Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI | 1 |
| Akanuma, N; Akutsu, Y; Hoshino, I; Isozaki, Y; Kono, T; Matsubara, H; Miyazawa, Y; Shiratori, T; Shuto, K; Uesato, M | 1 |
| Hayashi, K; Kuramochi, H; Nakamura, T; Narumiya, K; Ota, M; Sato, T; Shirai, Y; Yamamoto, M | 1 |
| Aoki, Y; Emi, M; Hamai, Y; Hihara, J; Kenjo, M; Murakami, Y; Okada, M | 1 |
| Chen, H; Zhang, T; Zhao, T | 1 |
| Aoki, T; Furukawa, H; Goto, Y; Imamoto, H; Imano, M; Kobayashi, K; Miki, H; Peng, YF; Takiuchi, H; Tamura, S; Tsujinaka, T | 1 |
| Hayakawa, T; Hirakata, A; Hosone, M; Katayama, H; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Takao, Y; Uchida, E; Umakoshi, M; Yokoyama, T; Yoshida, H | 1 |
| Cai, L; Guo, K; Hao, CL; Li, Z; Lin, P; Rong, TH; Wang, WP; Zhang, LJ; Zhang, Y; Zhu, JF | 1 |
| Haruma, K; Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M | 1 |
| Ellemann, AC; Kofoed, SC; Lundsgaard, M; Svendsen, LB | 1 |
| Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC | 1 |
| Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T | 1 |
| Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H | 1 |
| Bando, Y; Furukita, Y; Goto, M; Minato, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yamamoto, Y; Yoshida, T; Yuasa, Y | 1 |
| Choi, SR; Han, JS; Hsing, CT; Jang, JS; Kim, DC; Roh, MH; Ryu, SH; Woo, SM | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, DE; Na, KJ; Nam, TK; Shim, HJ | 1 |
| Baba, H; Baba, Y; Ishimoto, T; Iwatsuki, M; Kinoshita, K; Kurashige, J; Mimori, K; Nagai, Y; Saito, S; Watanabe, M | 1 |
| Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Hofheinz, RD; Hollerbach, S; Homann, N; Jäger, E; Kullmann, F; Luley, K; Mahlberg, R; Moehler, M; Pauligk, C; Prasnikar, N; Probst, S; Rethwisch, V; Stoehlmacher-Williams, J | 1 |
| Abd-Allah, D; El-Shazly, W; Khedr, G; Rostom, Y; Zaghloul, H | 1 |
| Bi, LW; Zhang, LZ; Zhao, HF | 1 |
| Capirci, C; Cordiano, C; de Manzoni, G; Grandinetti, A; Pasini, F; Pavarana, M; Rubello, D; Tomezzoli, A; Zanoni, A | 1 |
| Deguchi, K; Deguchi, T; Fukui, A; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Nomura, M; Omori, K; Takagi, M; Tamagawa, H; Tanaka, Y | 1 |
| Andoh, T; Arakawa, K; Itoh, H; Kobayashi, K; Sakamoto, K; Sato, H; Sunose, Y; Suto, Y; Takeyoshi, I; Tomizawa, N | 1 |
| Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E | 1 |
| Ades, S; Alcindor, T; Andalib, A; Artho, G; Chasen, M; Ferri, LE; Hickeson, M; Marcus, V; Thirlwell, MP | 1 |
| Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S | 1 |
| Abdel-Latif, RM; Anter, AH | 1 |
| Al-Batran, SE; Homann, N; Jäger, E; Lorenzen, S; Pauligk, C; Schmalenberg, H | 1 |
| Chen, X; Gao, Y; Hu, Z; Jiang, S; Liu, B; Liu, Y; Wu, Q; Zhang, X; Zhu, J | 1 |
| Bubis, JA; Dragnev, KH; Gordon, SR; Gui, J; Lisovsky, M; Rigas, JR; Sutton, JE; Wood, MD; Zaki, BI | 1 |
| Arnold, D; Brenner, B; Galle, PR; Gockel, I; Klautke, G; Lang, H; Moehler, M; Rödel, C; Roessler, HP; Schimanski, CC; Schmidberger, H; Thomaidis, T; Trarbach, T | 1 |
| Ajani, JA | 2 |
| Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F | 1 |
| Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Baker, SD; Faust, J; Govindan, R; Ma, MK; McLeod, HL; Perry, MC; Read, W; Trinkaus, K | 1 |
| Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H | 1 |
| Depisch, D; Hejna, M; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B | 1 |
| Boku, N; Chin, K; Fujita, H; Hamaguchi, T; Hyodo, I; Muro, K; Ohtsu, A; Ohtsu, T; Takiyama, W | 1 |
| Dempsey, DT; Furukawa, S; Gupta, D; McClurken, JB; Piacentino, V; Ross, K; Stepnowski, D | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Hennequin, C | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Bredenkamp, R; Duyster, J; Hennig, M; Lersch, C; Lordick, F; Lorenzen, S; Peschel, C; von Delius, S | 1 |
| Cetto, GL; Cordiano, C; de Manzoni, G; Durante, E; Gabbani, M; Grandinetti, A; Griso, C; Guglielmi, A; Maluta, S; Pasini, F; Pedrazzani, C; Pelosi, G; Tomezzoli, A | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY | 1 |
| Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E | 1 |
| Ebuchi, M; Hasegawa, K; Koide, A; Maruyama, M; Maruyama, S; Miyawaki, Y; Nagahama, T; Ohbu, M; Takashima, I; Tamura, N; Tanami, H | 1 |
| Ami, K; Ando, M; Nagahama, T; Ohbu, M | 1 |
| Andritzky, B; Boeters, I; Burkholder, I; Dürk, H; Edler, L; Görn, M; Horst, H; Hossfeld, DK; Laack, E; Lipp, R; Popp, J; Schuch, G | 1 |
| Brank, A; Camp, ER; Hochwald, SN; Li, J; Mackay, SL; Minnich, DJ | 1 |
| Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT | 1 |
| Endo, Y; Fujiwara, T; Hioki, M; Ikeda, Y; Kagawa, S; Kishimoto, H; Sakai, R; Tanaka, N; Urata, Y | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK | 1 |
| Ando, K; Kamata, T; Kitabayashi, H; Ochiai, T; Shimada, H; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Fujita, F; Fujita, M; Shakuto, S | 1 |
| Asanuma, F; Atsuda, K; Etou, T; Hiraku, O; Masuda, A; Miyagawa, T; Morinaga, S; Osaku, M; Sasaki, K; Suzuki, T; Suzuki, Y; Tongu, M; Yamada, T; Yamada, Y | 1 |
| Fujiwara, S; Hori, T; Iiri, T; Kobayashi, Y; Morita, S; Nonaka, M; Saito, Y; Sugitani, S | 1 |
| Hashimoto, Y; Hayashidani, Y; Morifuji, M; Murakami, Y; Sudo, A; Sueda, T; Sugiyama, Y; Uemura, K | 1 |
| Ardalan, B; Franceschi, D; Hamilton-Nelson, K; Lima, M; Livingstone, A; Parra, J; Ribeiro, A | 1 |
| Kitakata, H; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K | 1 |
| Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T | 2 |
| Aoki, T; Hoshino, S; Osaka, Y; Tachibana, S; Takagi, Y; Tsuchida, A | 1 |
| Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Miyazaki, S; Nemoto, K; Ohtsuka, K; Sakata, Y; Sakayori, M; Shibata, H; Shimodaira, H; Yoshioka, T | 1 |
| Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K | 1 |
| Ami, K; Ando, M; Ganno, H; Ito, T; Nagahama, T; Ohbu, M; Taira, M | 1 |
| Aoyama, N; Minamide, J; Oota, Y; Takada, K | 1 |
| Ancona, E; Boso, C; Chiarion-Sileni, V; Corti, L; Del Bianco, P; Innocente, R; Mazzarotto, R; Pigozzo, J; Ruol, A; Tomassi, O | 1 |
| Hashimoto, Y; Higashiyama, M; Inazawa, J; Ito, T; Kondo, K; Ortiz, C; Sakai, Y; Shimada, Y; Tanaka, E; Tsunoda, S | 1 |
| Bernini, M; Cordiano, C; de Manzoni, G; Giacopuzzi, S; Grandinetti, A; Minicozzi, AM; Pasini, F; Pedrazzani, C | 1 |
| Abad, A; Arellano, A; Boix, J; Cardenal, J; Casas, D; Fernández-Llamazares, J; Font, A; Manzano, JL; Margelí, M; Rosell, R | 1 |
| Chao, KS | 1 |
| Higashida, M; Hirabayashi, Y; Hirai, T; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K | 1 |
| Chiba, T; Fukushima, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Misawa, A; Mitsumori, M; Nishimura, T; Sakai, Y; Shimada, Y; Teramukai, S; Watanabe, G; Yanagihara, K; Yoshikawa, K | 1 |
| Fumoto, S; Kawahara, K; Noguchi, T; Shibata, T; Takahashi, Y; Takeno, S; Watanabe, S | 1 |
| Ilson, DH | 1 |
| Ajani, JA; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Marabotti, C; Moiseyenko, VM; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E | 1 |
| Ajani, JA; Awad, L; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Moiseyenko, VM; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E | 1 |
| Deeks, ED; Scott, LJ | 1 |
| Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H | 1 |
| Akerman, P; Berkenblit, A; Chauhan, B; Cruff, D; Evans, D; Habr, F; Harrington, D; Iannitti, D; Kennedy, T; Maia-Acuna, C; Miner, T; Safran, H; Sears, D; Stuart, K | 1 |
| Albertsson, M; Friesland, S; Frykholm, G; Johansson, B; Kadar, L; Letocha, H; Wagenius, G | 1 |
| Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H | 1 |
| Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M | 1 |
| Hayakawa, K; Higuchi, K; Ishiyama, H; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S | 1 |
| Honda, J; Matsuoka, H; Miyoshi, T; Seike, J; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y | 1 |
| Ba-Ssalamah, A; Brodowicz, T; Hejna, M; Pluschnig, U; Püspök, A; Raderer, M; Schmidinger, M; Zacherl, J; Zielinski, CC | 1 |
| Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Inui, T; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Benson, AB; Einzig, AI; Karp, DD; Neuberg, D; O'Dwyer, PJ; Remick, SC; Stewart, JA | 1 |
| Golomb, HM; Haraf, DJ; Hoffman, PC; Masters, GA; Mauer, AM; Vokes, EE; Watson, SM | 1 |
| Haraf, DJ; Hoffman, PC; Mauer, AM; Vokes, EE | 1 |
| Choy, H | 1 |
| Law, S; Wong, J | 1 |
| Guillet, G; Karam, A; Labat, JP; Leroy, JP; Metges, JP | 1 |
| Forastiere, AA; Heath, EI; Marshall, J; Piantadosi, S; Urba, S | 1 |
21 review(s) available for docetaxel anhydrous and Esophageal Neoplasms
| Article | Year |
|---|---|
Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2023 |
Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
Topics: Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Paclitaxel; Retrospective Studies; Taxoids | 2023 |
FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Stomach Neoplasms | 2023 |
Systematic review and meta-analysis of docetaxel perioperative chemotherapy regimens in gastric and esophagogastric tumors.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Esophageal Neoplasms; Humans; Perioperative Care; Stomach Neoplasms | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunotherapy; Irinotecan; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Stomach Neoplasms | 2020 |
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Ramucirumab; Stomach Neoplasms; Taxoids; Technology Assessment, Biomedical | 2017 |
The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2017 |
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Esophageal Fistula; Esophageal Neoplasms; Female; Humans; Oxonic Acid; Taxoids; Tegafur | 2017 |
[A case of skeletal muscle metastasis on the left thigh after esophagectomy for esophageal adenocarcinoma in Barrett' s esophagus].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Humans; Male; Middle Aged; Muscle, Skeletal; Recurrence; Taxoids | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Digestive System Surgical Procedures; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Europe; Fluorouracil; Humans; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Taxoids; Tegafur | 2015 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Taxoids | 2011 |
Docetaxel for gastric and esophageal carcinomas.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Clinical Trials as Topic; Docetaxel; Esophageal Neoplasms; Humans; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
[Association of taxanes and radiotherapy: preclinical and clinical studies].
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured | 2004 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Monitoring; Esophageal Neoplasms; Fluorouracil; Humans; Patient Selection; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Docetaxel: in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Stomach Neoplasms; Taxoids | 2007 |
Taxanes in combined-modality therapy for solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids | 1999 |
New adjuvant therapies for esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2001 |
153 trial(s) available for docetaxel anhydrous and Esophageal Neoplasms
| Article | Year |
|---|---|
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.
Topics: Antibodies, Monoclonal, Humanized; Docetaxel; Esophageal Neoplasms; Humans; Japan | 2022 |
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Food, Formulated; Humans; Prospective Studies | 2021 |
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2022 |
A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Radiation Dosage | 2022 |
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans | 2022 |
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Stomach Neoplasms; Tumor Microenvironment | 2022 |
Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2022 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neoplasms; Treatment Outcome | 2023 |
Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Follow-Up Studies; Humans; Prospective Studies | 2023 |
Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Japan; Male; Middle Aged; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Proton Therapy; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome | 2019 |
Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Filgrastim; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Prospective Studies | 2019 |
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Nivolumab; Taxoids; Treatment Outcome; Young Adult | 2020 |
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Survival Rate; Young Adult | 2020 |
Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase III Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08).
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Humans; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Treatment Outcome | 2022 |
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Female; Gossypol; Humans; Male; Mice; Middle Aged; Neoplastic Stem Cells; Pilot Projects; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms | 2021 |
A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Stomach Neoplasms; Survival Rate | 2021 |
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2021 |
Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Postoperative Period; Radiotherapy, Intensity-Modulated; Survival Analysis; Taxoids | 2017 |
Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2018 |
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate | 2018 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Humans; Maximum Tolerated Dose; Oxonic Acid; Prospective Studies; Taxoids; Tegafur | 2018 |
Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Preoperative Period; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated; Remission Induction; ROC Curve; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2019 |
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Polyethylene Glycols; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2019 |
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2020 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Camptothecin; Docetaxel; Drug Carriers; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nanocapsules; Stomach Neoplasms; Survival Rate; Taxoids | 2013 |
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Humans; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids | 2013 |
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
Phase II study of docetaxel (Aisu®) combined with three- dimensional conformal external beam radiotherapy in treating patients with inoperable esophageal cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Conformal; Taxoids | 2012 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex | 2013 |
Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome; United States | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2013 |
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Thoracotomy; Treatment Outcome | 2013 |
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
[A randomized controlled trial of intensity-modulated radiation therapy plus docetaxel and cisplatin versus simple intensity-modulated radiation therapy in II-III stage esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Prospective Studies; Radiography; Radiotherapy, Intensity-Modulated; Taxoids | 2013 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Taxoids | 2013 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Taxoids; Treatment Failure; Vomiting | 2016 |
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids | 2014 |
Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Panitumumab; Taxoids; Treatment Outcome | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Feasibility Studies; Febrile Neutropenia; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Taxoids | 2014 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2014 |
Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2014 |
Clinical observation and therapeutic evaluation of Rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Down-Regulation; Endostatins; Esophageal Neoplasms; Female; Humans; Male; Neovascularization, Pathologic; Radiography; Taxoids; Vascular Endothelial Growth Factor A | 2014 |
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Turkey | 2014 |
Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome | 2015 |
Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Research Design; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2015 |
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome | 2015 |
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Young Adult | 2015 |
[Clinical evaluations of neoadjuvant chemotherapy with DN and FP regimens for patients with middle or lower thoracic locally advanced esophageal squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Survival Rate; Taxoids | 2015 |
A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagitis; Feasibility Studies; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Pneumonia; Radiotherapy Dosage; Stomatitis; Taxoids | 2015 |
Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Taxoids | 2015 |
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Genetic Predisposition to Disease; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients.
Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Cisplatin; Docetaxel; Endpoint Determination; Esophageal Neoplasms; Febrile Neutropenia; Feces; Female; Fluorouracil; Gastrointestinal Microbiome; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Neoadjuvant Therapy; Patient Compliance; Propionates; Prospective Studies; Serum Albumin; Synbiotics; Taxoids; Young Adult | 2017 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Research Design; Taxoids; Treatment Outcome | 2017 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Fluorouracil; Humans; Infections; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Panitumumab; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2016 |
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Epidemiologic Methods; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Taxoids; Treatment Outcome | 2016 |
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids | 2016 |
The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2016 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Treatment Outcome | 2016 |
Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Treatment Outcome | 2016 |
Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study.
Topics: Abdomen; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Endoscopy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Thorax; Tomography, X-Ray Computed | 2016 |
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Quality of Life; Stomach Neoplasms; Taxoids | 2016 |
A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids | 2016 |
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2017 |
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Rate; Taxoids | 2016 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2008 |
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2009 |
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy; Taxoids; Treatment Outcome | 2009 |
Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome | 2010 |
A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Neutropenia; Taxoids | 2010 |
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2009 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Taxoids | 2010 |
Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia | 2010 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Therapy, Combination; Endosonography; Esophageal Neoplasms; Esophagus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome; United States | 2010 |
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Outpatients; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2010 |
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Interactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2011 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Fluorouracil; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Vomiting | 2010 |
Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2010 |
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Preoperative Care; Radiotherapy Dosage; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Taxoids | 2011 |
[Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Cystic Fibrosis; Docetaxel; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Young Adult | 2010 |
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Taxoids | 2011 |
A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Floxuridine; Follow-Up Studies; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome | 2011 |
Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids | 2011 |
[Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids | 2011 |
[Intensity-modulated or 3-D conformal radiotherapy combined with chemotherapy with docetaxel and cisplatin for locally advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Radiotherapy, Conformal; Taxoids | 2011 |
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Taxoids; Treatment Outcome | 2011 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Perioperative Period; Stomach Neoplasms; Taxoids; Tumor Burden; Young Adult | 2012 |
Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome | 2011 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Taxoids; Time Factors; Treatment Outcome | 2012 |
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids | 2012 |
Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Taxoids | 2012 |
Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2012 |
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2012 |
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2012 |
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Taxoids | 2013 |
Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids | 2013 |
Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult | 2013 |
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Radiotherapy, High-Energy; Remission Induction; Taxoids; Vomiting | 2012 |
Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Prospective Studies; Taxoids | 2013 |
The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult | 2013 |
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Prognosis; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids | 2013 |
Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Germany; Humans; Israel; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2013 |
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2002 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Therapy, Combination; Erythropoietin; Esophageal Neoplasms; Esophagogastric Junction; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2003 |
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids | 2005 |
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Germany; Humans; Lymphatic Metastasis; Male; Middle Aged; Pilot Projects; Prevalence; Taxoids; Treatment Outcome | 2005 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Radiotherapy Dosage; Radiotherapy, Adjuvant; Taxoids; Tegafur | 2006 |
[Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Taxoids | 2007 |
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Taxoids | 2007 |
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Comorbidity; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids | 2007 |
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Treatment Outcome | 2007 |
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein | 2008 |
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Taxoids | 2008 |
Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Stud
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Erythropoietin; Esophageal Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2008 |
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids | 1996 |
Phase I study of docetaxel with concomitant thoracic radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Taxoids; Treatment Outcome | 1998 |
Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2002 |
253 other study(ies) available for docetaxel anhydrous and Esophageal Neoplasms
| Article | Year |
|---|---|
Study of the radiosensitization of docetaxel in human esophageal squamous carcinoma ECA109 cell line.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; Radiation, Ionizing | 2021 |
Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2021 |
Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bias; Biomarkers, Tumor; Carboplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Nomograms; Support Vector Machine; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2022 |
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Docetaxel; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Perioperative Care; Propensity Score; Stomach Neoplasms; Treatment Outcome | 2022 |
Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Larynx; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Prognosis; Treatment Outcome | 2022 |
Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrastim; Fluorouracil; Humans; Lymphoma, Follicular; Neutropenia; Polyethylene Glycols; Retrospective Studies | 2022 |
Synergistic effects of BAY606583 on docetaxel in esophageal cancer through modulation of ERK1/2.
Topics: Apoptosis; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; MAP Kinase Signaling System | 2022 |
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms | 2023 |
Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Translocation, Genetic | 2022 |
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Propensity Score; Retrospective Studies; Taxoids | 2022 |
Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoadjuvant Therapy; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China.
Topics: Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Nivolumab; Paclitaxel | 2022 |
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasms, Second Primary; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Single-Center Analysis of Pegfilgrastim-induced Aortitis Using a Drug Prescription Database and CT Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aortitis; Breast Neoplasms; Cisplatin; Docetaxel; Drug Prescriptions; Esophageal Neoplasms; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2022 |
Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
Topics: Aged; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Retrospective Studies | 2022 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Taxoids | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Male; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2023 |
Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies | 2023 |
Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2023 |
Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers.
Topics: Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; East Asian People; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Pneumonia; Postoperative Complications; Prognosis; Retrospective Studies | 2023 |
Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neutropenia; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Female; Fluorouracil; Humans; Male; Retrospective Studies | 2023 |
Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Retrospective Studies; Stomach Neoplasms | 2023 |
Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer.
Topics: Aged; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Muscles; Neoadjuvant Therapy; Retrospective Studies; Risk Factors | 2023 |
Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Induction Chemotherapy; Treatment Outcome | 2023 |
[A Case of Specific Pneumonia Diagnosed as Peritumoral Infiltration during Nivolumab Treatment for Esophageal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Pneumonia | 2023 |
Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Febrile Neutropenia; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Retrospective Studies | 2023 |
The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer.
Topics: Antineoplastic Agents, Immunological; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Nivolumab; Nutritional Status; Paclitaxel; Retrospective Studies | 2023 |
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutition Disorders; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Quality of Life; Retrospective Studies; Survival Rate | 2019 |
Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Prognosis | 2019 |
Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Retrospective Studies; Treatment Outcome | 2020 |
[Preoperative Chemotherapy with DCF for Advanced Esophageal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Retrospective Studies; Taxoids; Treatment Outcome | 2019 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Lymph Nodes; Mediastinum; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2019 |
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prospective Studies; Stomach Neoplasms | 2020 |
Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Febrile Neutropenia; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vocal Cord Paralysis | 2020 |
Metabolic response assessment and PET-guided treatment of esophageal cancer.
Topics: Adenocarcinoma; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Positron-Emission Tomography | 2020 |
USP9X mRNA expression predicts clinical outcome for esophageal squamous cell carcinoma treated with cisplatin-based therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Radiotherapy, Adjuvant; RNA, Messenger; Ubiquitin Thiolesterase | 2020 |
[A Case of Esophageal Cancer Achieving a Pathological Complete Response after Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Male; Neoadjuvant Therapy | 2019 |
Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Combined Modality Therapy; Creatinine; Docetaxel; Esophageal Neoplasms; Female; Humans; Incidence; Kidney Function Tests; Male; Neoplasm Staging; Radiotherapy; Retrospective Studies; Safety; Survival Rate | 2020 |
Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antineoplastic Agents; Azepines; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Hippo Signaling Pathway; Humans; Mice, Nude; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Transcription Factors; Transcription, Genetic; Triazoles; YAP-Signaling Proteins | 2020 |
A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Squamous Cell; Treatment Outcome; Young Adult | 2020 |
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Prognosis; Rad51 Recombinase; Treatment Outcome | 2022 |
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Mucosa; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagoscopy; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Retrospective Studies | 2021 |
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; United States | 2020 |
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Hospital Mortality; Humans; Length of Stay; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Postoperative Complications; Propensity Score; Survival Rate; Treatment Outcome | 2020 |
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Polymorphism, Genetic; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2020 |
Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Induction Chemotherapy; Retrospective Studies; Treatment Outcome | 2021 |
Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Japan; Lymphatic Metastasis; Male; Middle Aged; Postoperative Complications; Prognosis; Treatment Outcome | 2020 |
Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer.
Topics: Animals; Antineoplastic Agents; Curcumin; Docetaxel; Drug Carriers; Drug Liberation; Esophageal Neoplasms; Humans; Hydrogen-Ion Concentration; Nanomedicine; Nanoparticles; Polyethylene Glycols; Polyethyleneimine; Tumor Microenvironment | 2020 |
A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils | 2021 |
A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Quinazolines; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Survival Rate; Thiophenes; Treatment Outcome | 2021 |
ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma.
Topics: Carcinogenesis; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans | 2021 |
Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Stomach Neoplasms; Taxoids | 2021 |
Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Esophageal Neoplasms; Female; Humans; Macula Lutea; Macular Edema; Male; Middle Aged; Ovarian Neoplasms; Taxoids; Tomography, Optical Coherence; Visual Acuity | 2017 |
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Area Under Curve; Blood Platelets; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Platelet Count; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; ROC Curve; Taxoids | 2017 |
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Rate; Taxoids | 2017 |
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Oxaliplatin | 2017 |
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Sarcopenia; Taxoids | 2017 |
A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Cycle; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Compounding; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Humans; Nanostructures; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2018 |
Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Rate; Thoracoscopy; Treatment Outcome | 2018 |
Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Nano Let‑7b sensitization of eliminating esophageal cancer stem‑like cells is dependent on blockade of Wnt activation of symmetric division.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Male; MicroRNAs; Middle Aged; Nanomedicine; Neoplastic Stem Cells; Retinal Dehydrogenase; Retrospective Studies; RNA, Long Noncoding; Taxoids; Wnt Signaling Pathway | 2017 |
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Proto-Oncogene Mas; Taxoids; Treatment Outcome | 2017 |
Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Propensity Score; Taxoids; Treatment Outcome | 2018 |
Adverse Prognostic Factors of Advanced Esophageal Cancer in Patients Undergoing Induction Therapy with Docetaxel, Cisplatin and 5-Fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids | 2018 |
[Case Report of an Acute Focal Bacterial Nephritis Associated with Adjuvant Chemotherapy in Esophageal Cancer Patient].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Middle Aged; Nephritis; Taxoids | 2017 |
[A Case of Advanced Esophageal Cancer Successfully Treated with DCF Chemotherapy Followed by Conversion Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Taxoids; Treatment Outcome | 2017 |
[A Case of Metachronous Resection for Advanced Esophageal Cancer with Pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Male; Pheochromocytoma; Taxoids | 2017 |
[Outcome of Patients with Pathological Complete Response after Neoadjuvant Chemotherapy in Advanced Esophageal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2017 |
[A Case of Emergency Resection of Esophageal Cancer Which is on the Brink of Perforation after Neoadjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Emergency Medical Services; Esophageal Neoplasms; Esophageal Perforation; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids | 2017 |
[Three-Year Survival after Lymphadenectomy for Residual Lymph Node Metastasis of Esophageal Cancer with Invasion into the Trachea and Carotid Artery after Chemoradiotherapy - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carotid Arteries; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Invasiveness; Taxoids; Trachea | 2017 |
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Nomograms; Oxaliplatin; Positron Emission Tomography Computed Tomography; Preoperative Period; Radiopharmaceuticals; Radiotherapy Dosage; Risk Assessment; Sex Factors; Survival Rate | 2018 |
Esophageal Metastases from Breast Carcinoma: a Rare Delayed Metastases After 15 Years.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Docetaxel; Dose Fractionation, Radiation; Esophageal Mucosa; Esophageal Neoplasms; Esophagoscopy; Female; Humans; Lymph Node Excision; Mastectomy, Segmental; Middle Aged; Positron Emission Tomography Computed Tomography; Time Factors; Treatment Outcome | 2019 |
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Taxoids | 2018 |
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Survival Rate | 2018 |
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Prognosis; Retrospective Studies; Treatment Outcome | 2018 |
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; Chromones; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Delivery Systems; Drug Therapy, Combination; Esophageal Neoplasms; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanomedicine; Neoplasm Invasiveness; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Nucleus; Chemoradiotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F-Box-WD Repeat-Containing Protein 7; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies; Taxoids | 2018 |
Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Filgrastim; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Retrospective Studies | 2018 |
[Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrastim; Fluorouracil; Humans; Neutropenia; Polyethylene Glycols; Prospective Studies; Retrospective Studies; Taxoids | 2018 |
Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cryotherapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Ice; Infusions, Intravenous; Male; Middle Aged; Quality of Life; Retrospective Studies; Stomatitis; Treatment Outcome | 2019 |
Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Platinum Compounds; Prognosis; Survival Analysis | 2019 |
[A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Taxoids | 2018 |
[Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrastim; Fluorouracil; Humans; Male; Polyethylene Glycols; Taxoids | 2019 |
The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Second Primary; Progression-Free Survival | 2019 |
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Contrast Media; Deglutition Disorders; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Perforation; Esophageal Stenosis; Esophagectomy; Fluorouracil; Follow-Up Studies; Humans; Male; Neoadjuvant Therapy; Risk Assessment; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagoscopy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome | 2020 |
Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
Topics: Adult; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Case-Control Studies; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Lymphocyte Activation Gene 3 Protein; Male; Middle Aged; Prognosis; Programmed Cell Death 1 Receptor; Receptors, Virus | 2019 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Operative Time; Retrospective Studies; Thoracoscopy; Treatment Outcome | 2020 |
Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Topics: Adult; Age Factors; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Male; Middle Aged; Neoadjuvant Therapy; Residence Characteristics; Retrospective Studies; Risk Factors | 2020 |
[A case of far advanced-esophageal squamous cell carcinoma successfully treated with docetaxel].
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Taxoids | 2013 |
Esophageal mucosal metastasis from adenocarcinoma of the distal stomach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cisplatin; Disease Progression; Docetaxel; Endoscopy, Digestive System; Endosonography; Esophageal Neoplasms; Esophagus; Gastrectomy; Humans; Immunohistochemistry; Male; Middle Aged; Mucin 5AC; Mucous Membrane; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2013 |
[Pathological complete response in a case of advanced esophageal cancer invading aorta treated by preoperative chemotherapy with docetaxel and cisplatin plus 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Taxoids | 2013 |
[A case of advanced esophagogastric junction cancer responding to pre-operative combination chemotherapy of docetaxel, cisplatin, S-1, and trastuzumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Middle Aged; Taxoids; Trastuzumab | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
Second-line chemotherapy for patients with oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Stomach Neoplasms; Taxoids | 2014 |
[Current status of neoadjuvant chemotherapy for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2013 |
[A case of liver metastasis from esophageal cancer treated with stereotactic body radiation therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Organoplatinum Compounds; Recurrence; Taxoids; Treatment Outcome; Whole-Body Irradiation | 2013 |
[Study of decreased oral intake in patients receiving neoadjuvant chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Eating; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Taxoids | 2013 |
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2014 |
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Proportional Hazards Models; Retrospective Studies; Taxoids | 2016 |
Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cisplatin; Docetaxel; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptide Initiation Factors; Proportional Hazards Models; Protein Binding; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Taxoids; Time Factors; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Taxoids | 2014 |
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prognosis; Survival Rate; Taxoids | 2014 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2015 |
Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids | 2014 |
High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.
Topics: Adult; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Taxoids; Young Adult | 2014 |
Antitumor Efficacy of Docetaxel-loaded Nanocarrier against Esophageal Cancer Cell Bearing Mice Model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chitosan; Docetaxel; Drug Carriers; Drug Delivery Systems; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Male; Mice; Mice, Nude; Nanoparticles; Taxoids | 2015 |
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoadjuvant Therapy; Neoplasm Staging; Shoulder; Survival Rate; Taxoids | 2015 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutition Disorders; Docetaxel; Enteral Nutrition; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Quality of Life; Taxoids | 2015 |
Benefit of neoadjuvant chemotherapy for Siewert type II esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Effectiveness of proton beam therapy on liver metastases of esophageal cancer: report of a case.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Proton Therapy; Radiography; Taxoids | 2015 |
[Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recurrence; Taxoids | 2014 |
Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Care; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Esophageal Neoplasms; Female; Gene Expression; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Transport Proteins; Middle Aged; Precision Medicine; Prognosis; Response Evaluation Criteria in Solid Tumors; RNA, Messenger; ROC Curve; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2015 |
Engineering Stent Based Delivery System for Esophageal Cancer Using Docetaxel.
Topics: Animals; Delayed-Action Preparations; Docetaxel; Drug Delivery Systems; Esophageal Neoplasms; Esophagus; Polymers; Stents; Swine; Taxoids | 2015 |
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Propensity Score; Retrospective Studies; Taxoids | 2015 |
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2016 |
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Male; MAP Kinase Kinase Kinases; Middle Aged; Neoplasm Proteins; Radiation Tolerance; RNA, Messenger; ROC Curve; Taxoids; Ubiquitin-Protein Ligases; Zearalenone | 2015 |
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Paclitaxel; Peptide Initiation Factors; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Taxoids | 2015 |
The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial.
Topics: Adenocarcinoma; Cost-Benefit Analysis; Docetaxel; Esophageal Neoplasms; Gastrointestinal Neoplasms; Health Care Costs; Humans; Quality-Adjusted Life Years; Taxoids | 2016 |
[Complete Response in Far-Advanced Esophageal Cancer Treated with Induction Chemotherapy Followed by Definitive Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Remission Induction; Taxoids | 2015 |
[A Case of Resected Gastric Cancer Invading the Esophagus with Esophageal Recurrence That Responded to Weekly Docetaxel／Cisplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagus; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Recurrence; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; DNA Breaks, Double-Stranded; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Taxoids | 2016 |
Plasma ghrelin levels as a predictor of adverse renal events due to cisplatin-based chemotherapy in patients with esophageal cancer.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Ghrelin; Humans; Male; Middle Aged; Severity of Illness Index; Taxoids | 2016 |
Planned Esophagectomy after Neoadjuvant Hyperthermo-Chemoradiotherapy using Weekly Low-Dose Docetaxel and Hyperthermia for Advanced Esophageal Carcinomas.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagitis; Female; Humans; Hyperthermia, Induced; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Early Detection of Cancer; Endoscopy, Digestive System; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Microwaves; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome; Ultrasonography | 2016 |
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Prognosis; Retrospective Studies; Survival Analysis; Taxoids | 2016 |
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression; Genetic Association Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids | 2017 |
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Pneumonia; Propensity Score; Taxoids; Thrombocytopenia | 2016 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; France; Humans; Male; Middle Aged; Propensity Score; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids | 2016 |
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Taxoids; Tumor Suppressor Protein p53 | 2017 |
AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime).
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Taxoids; Treatment Outcome | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrectomy; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2016 |
[Second-line treatment for metastatic or locally advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Molecular Targeted Therapy; Paclitaxel; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Taxoids | 2016 |
[Concurrent chemoradiotherapy followed by docetaxel and cisplatin consolidation chemotherapy in elderly patients with esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagitis; Female; Hematologic Diseases; Humans; Male; Radiotherapy, Intensity-Modulated; Remission Induction; Taxoids | 2016 |
Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Postoperative Complications; Taxoids | 2017 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Period; Preoperative Care; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2017 |
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Metastasis; Parenteral Nutrition; Taxoids | 2016 |
[Pathological Complete Response in a Case of Advanced Esophageal Cancer with Widespread Lymph Node Metastases Treated Using Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-FU(DCF therapy)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Taxoids | 2016 |
A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cyclooctanes; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Esophageal Neoplasms; Humans; Inhibitory Concentration 50; Lignans; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polycyclic Compounds; Solubility; Surface Properties; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
[Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Recurrence; Taxoids; Time Factors; Treatment Outcome | 2017 |
Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Period; Preoperative Period; Retrospective Studies; Stomach Neoplasms; Surgical Procedures, Operative; Survival Analysis; Switzerland; Taxoids; Young Adult | 2017 |
Different functions of DEPTOR in modulating sensitivity to chemotherapy for esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Survivin; Taxoids | 2017 |
[A Case of Resected Advanced Esophageal Cancer That Responded to Combination Therapy Comprising Docetaxel, Cisplatin, and 5-Fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2017 |
Correlation between loss of Bcl-XL expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Caspase 3; Caspase 8; Chemotherapy, Adjuvant; Combined Modality Therapy; DNA Primers; Docetaxel; Esophageal Neoplasms; Fas-Associated Death Domain Protein; Female; Gene Expression; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids | 2008 |
[A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagoscopes; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Taxoids; Tomography, X-Ray Computed | 2008 |
Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis.
Topics: Acute Disease; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Fluorodeoxyglucose F18; Hepatitis; Humans; Liver; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals; Taxoids | 2008 |
Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Probability; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Integrin beta1; Models, Biological; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Taxoids | 2008 |
[A case of esophageal cancer patient who developed tumor lysis syndrome after chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Organoplatinum Compounds; Taxoids; Tomography, X-Ray Computed; Tumor Lysis Syndrome | 2008 |
[A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagoscopy; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Male; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2009 |
Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2009 |
[A case of the oldest old patient with advanced esophageal cancer responding completely to the combination chemotherapy of docetaxel/5-fluorouracil/nedaplatin with radiation].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Organoplatinum Compounds; Taxoids | 2009 |
[PSK-mediated growth suppression and enhancement of 5-FU/docetaxel-induced cytotoxicity in human esophageal cancer cell lines].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Proteoglycans; Taxoids | 2009 |
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Humans; Liver Neoplasms; Male; Oxonic Acid; Taxoids; Tegafur | 2009 |
Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2010 |
A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2010 |
[An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deglutition; Docetaxel; Esophageal Neoplasms; Fatal Outcome; Humans; Male; Myocardial Infarction; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quality of Life; Renal Dialysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Taxoids | 2010 |
[A case of advanced esophageal cancer with no recurrence treated biweekly with postoperative docetaxel/nedaplatin combined chemotherapy after non-curative surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Neoplasm Staging; Organoplatinum Compounds; Remission Induction; Taxoids | 2010 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagoscopy; Gastroscopy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Denmark; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fever; Fluorouracil; Humans; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, nedaplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatal Outcome; Fluorouracil; Humans; Male; Neoplasm Staging; Organoplatinum Compounds; Stomach Neoplasms; Taxoids | 2010 |
[Early prediction of treatment response by serum CRP levels in patients with advanced esophageal cancer who underwent definitive chemoradiotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; C-Reactive Protein; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2010 |
[Docetaxel with concurrent radiotherapy in patients with inoperable or relapsed oesophageal cancer].
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2010 |
[A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Remission Induction; Stents; Taxoids; Trachea; Tracheal Neoplasms; Tracheal Stenosis | 2010 |
[Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy--a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Salvage Therapy; Taxoids | 2010 |
[A case successfully treated with subtotal esophagectomy after preoperative second-line chemotherapy for cT4 esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Male; Taxoids | 2010 |
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Antineoplastic Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Esophageal Achalasia; Esophageal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Intestinal Polyposis; Liver Neoplasms; Male; Neoplastic Syndromes, Hereditary; Peritoneal Neoplasms; Proton Pump Inhibitors; Taxoids; Trastuzumab | 2011 |
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
[A case of advanced esophageal carcinoma with nephrotic syndrome completely responding to chemotherapy of docetaxel, nedaplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Staging; Nephrotic Syndrome; Organoplatinum Compounds; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2011 |
Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cisplatin; Docetaxel; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Membrane Glycoproteins; Membrane Proteins; Middle Aged; Neoplasm Proteins; Prognosis; Survival Rate; Sweden; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Remission Induction; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoplasm Staging; Prognosis; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Taxoids | 2011 |
Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.
Topics: Antineoplastic Agents; Beverages; Carcinoma, Squamous Cell; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Esophageal Neoplasms; Female; Food-Drug Interactions; Humans; Middle Aged; Taxoids | 2011 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome | 2011 |
Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Docetaxel; Drug Synergism; Esophageal Neoplasms; Female; Humans; Mad2 Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Repressor Proteins; src-Family Kinases; Taxoids; Thiazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Male; Massage; Middle Aged; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2011 |
[Complete response in a patient with liver metastasis of esophageal squamous cell carcinoma treated with docetaxel].
Topics: Aged; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Liver Neoplasms; Male; Taxoids; Tomography, X-Ray Computed | 2011 |
[A case of a patient with stage IVa esophageal cancer surviving over 4 years by combination chemotherapy with docetaxel,5 -FU and cisplatin, without operation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids; Tomography, X-Ray Computed | 2011 |
Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; ErbB Receptors; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2012 |
Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Postoperative Complications; Recurrence; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Japan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2012 |
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids | 2011 |
Hand and foot syndrome associated with docetaxel treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Foot Dermatoses; Hand Dermatoses; Humans; Taxoids; Treatment Outcome | 2012 |
[Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Recurrence; Retrospective Studies; Salvage Therapy; Taxoids | 2011 |
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Fatal Outcome; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2012 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Taxoids; Tegafur | 2012 |
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Multiple Primary; Stomach Neoplasms; Taxoids | 2012 |
The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids | 2012 |
A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2012 |
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabine; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Deglutition Disorders; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Perforation; Esophagogastric Junction; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prosthesis Failure; Retrospective Studies; Stents; Taxoids | 2012 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Taxoids; Time Factors | 2013 |
Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Topics: Aged; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hyaluronan Receptors; Isoenzymes; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Proportional Hazards Models; Retinal Dehydrogenase; Retrospective Studies; Taxoids | 2013 |
A case of synchronous esophagus and stomach cancer successfully treated by combined chemotherapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Cisplatin; Docetaxel; Drug Therapy, Combination; Endoscopy, Digestive System; Esophageal Neoplasms; Humans; Male; Positron-Emission Tomography; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed | 2012 |
RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Hexosyltransferases; Humans; Male; Neoadjuvant Therapy; Proteasome Endopeptidase Complex; Taxoids | 2012 |
[Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Taxoids; Vomiting | 2012 |
[Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Taxoids | 2012 |
[A case of Barrett's esophageal carcinoma treated with combined therapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids | 2012 |
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Hospitals, High-Volume; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2013 |
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2013 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Thoracic Neoplasms; Tomography, X-Ray Computed | 2013 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prognosis; Taxoids | 2003 |
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Humans; Ligation; Male; Middle Aged; Neoplasm Metastasis; Parenteral Nutrition, Total; Peritoneovenous Shunt; Pleural Effusion; Postoperative Complications; Respiration, Artificial; Taxoids; Thoracostomy; Thoracotomy; Tissue Adhesives | 2004 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Taxoids; Treatment Outcome | 2005 |
[The docetaxel radiosensitization experience for the treatment of unresectable esophageal cancer].
Topics: Aged; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids | 2005 |
[Weekly docetaxel in combination with concomitant radiotherapy for esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids | 2005 |
Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorouracil; Genes, Reporter; Humans; Kinetics; Luciferases; NF-kappa B; Taxoids | 2006 |
Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Docetaxel; Drug Carriers; Esophageal Neoplasms; Feasibility Studies; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Polymerase Chain Reaction; Stomach Neoplasms; Taxoids; Telomerase; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2006 |
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Taxoids; Treatment Outcome; X-Rays; Xenograft Model Antitumor Assays | 2006 |
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous | 2006 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oxonic Acid; Pyridines; Succinate Dehydrogenase; Taxoids; Tegafur; Thymidylate Synthase; Tumor Cells, Cultured | 2006 |
[A case of recurrent esophageal cancer with lung metastases successfully treated with docetaxel-combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Lung Neoplasms; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2006 |
Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Endosonography; Esophageal Neoplasms; Female; Floxuridine; Humans; Leucovorin; Lymph Nodes; Male; Neoadjuvant Therapy; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Quality of Life; Remission Induction; Taxoids; Tegafur | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Taxoids; Tegafur | 2006 |
Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2006 |
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Remission Induction; Salvage Therapy; Taxoids | 2006 |
[A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2006 |
The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bronchi; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pericardium; Taxoids; Trachea | 2007 |
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2007 |
[A feasible study of docetaxel/nedaplatin combined chemotherapy for relapsed or refractory esophageal cancer patients as a 2nd-line chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Humans; Infusions, Intravenous; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2007 |
Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2007 |
[A case of recurrent esophageal cancer successfully treated with concurrent radiochemotherapy with low-dose docetaxel plus 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Remission Induction; Taxoids | 2007 |
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Quality of Health Care; Taxoids; Tegafur; Uracil | 2007 |
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2007 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Fluorouracil; Gastroscopy; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed | 2008 |
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vindesine | 2008 |
Squamous syringometaplasia associated with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Metaplasia; Middle Aged; Necrosis; Paclitaxel; Sweat Gland Neoplasms; Sweat Glands; Taxoids | 2002 |